Home › Weight Loss › Mounjaro UK › Buy Mounjaro UK

Buy Mounjaro Online in the UK

Looking to buy Mounjaro in the UK? This guide explains exactly how to do it safely from a GPhC-registered pharmacy: who is eligible, what the clinical assessment involves, how your identity and weight are verified, how prescriptions are approved and why they are sometimes declined, and what happens from your first consultation through to tracked delivery. Mounjaro is a prescription-only medicine, so buying it means being assessed and prescribed for rather than simply adding it to a basket.

✍️ Written and clinically reviewed by Shadeia Younis, Superintendent Pharmacist (GPhC No. 2052119) · SCOPE certified in obesity management · 25 years’ pharmacy experience
Last reviewed: 3rd August 2026 · Prices last verified: 3rd August 2026

Can you buy Mounjaro in the UK?

Yes, on prescription. Mounjaro (tirzepatide) is a prescription-only medicine in the UK, which means it can only be supplied against a prescription written by a registered prescriber who has assessed you1. That is not a formality and it is not something a legitimate provider can skip.

What that means in practice

Three things have to happen before a pen can lawfully reach you. A prescriber has to assess whether the medicine is safe and appropriate for you specifically. A prescription has to be issued. And a registered pharmacy has to dispense it. A provider offering to bypass any of those is not operating within UK medicines law, whatever their website says.

The three routes

Buying online is not a lesser route. A regulated online pharmacy works to the same standards as a high-street one, is on the same register, and is inspected by the same regulator5. What differs is convenience and, frequently, price. Our price comparison guide covers the cost side in detail.

Where to buy Mounjaro safely in the UK

Demand has created a market operating outside the regulated supply chain. The MHRA has taken enforcement action against falsified and unlicensed weight-loss injections entering the UK and has issued public warnings about buying from unregulated sources6. The difficulty for a patient is that a legitimate and an illegitimate provider can look similar at a glance.

Nine checks before you order anywhere

LegitScript certification is a useful additional signal, but it is a private certification scheme rather than UK regulation. GPhC registration is the statutory requirement and the one that matters most.

Who can buy Mounjaro?

Private eligibility follows the terms of the UK licence, then narrows according to each provider’s clinical governance. Two people with identical BMIs can get different answers, and that is the assessment working rather than failing. If you are weighing tirzepatide against semaglutide first, see our Mounjaro versus Wegovy comparison.

Weight-related conditions that may qualify at BMI 27 to under 30

• Type 2 diabetes
• Prediabetes
• High blood pressure
• Dyslipidaemia, including raised cholesterol
• Obstructive sleep apnoea
• Cardiovascular disease

Lower BMI thresholds are commonly applied for some ethnic backgrounds, in line with NICE guidance on assessing BMI2. Your prescriber will apply the criteria that fit your individual assessment. Our full eligibility guide covers this in more depth, including how private criteria differ from the NHS funding criteria.

How to buy Mounjaro online, step by step

The whole process at Slinic, from first click to your medicine arriving.

What the clinical assessment actually asks

People often worry about this part, usually because they are unsure how much detail is expected or whether something in their history will rule them out. It is worth being clear about what is asked and why, because the assessment only protects you if it is complete.

What to have ready before you start

• An accurate current weight — weigh yourself rather than estimating
• A list of your medicines with doses and the times of day you take them
• Photo ID
• If you are transferring from another provider: your current strength, how long you have been on it, the date of your last dose, and evidence such as a dispensing label or order history

Identity and weight verification

Two checks that separate a regulated provider from one cutting corners, and the two most people are least expecting.

Why identity is checked

A prescription is a legal document issued to a named individual. Verifying identity confirms that the person being assessed is the person receiving the medicine, prevents a prescription being obtained on someone else’s behalf, and protects against age-related and duplicate-supply risks. Methods vary between providers — photo identification, video consultation, or both.

Why weight is verified independently

BMI determines eligibility, and eligibility determines whether a prescription can lawfully be issued. A provider that prescribes on a self-reported figure alone has no way of knowing whether the criteria are actually met. GPhC guidance for pharmacy services provided at a distance sets expectations here5, and it is one of the most common areas where less careful providers fall short.

Summary Care Record checks and your GP

A common question, and one where practice varies between providers.

What a Summary Care Record is

An electronic summary of key information from your GP record — current medicines, allergies and previous adverse reactions as a minimum, with additional information where you have consented to it7. It exists so that a clinician treating you outside your GP practice can see the essentials.

How it is used in private prescribing

Where a provider has access and you consent, checking it corroborates what you have reported: the medicines you are taking, allergies, and relevant conditions. It is a safety check rather than a hurdle, and it is one of the ways a remote assessment can be made closer to a face-to-face one. Access requires your consent and is not automatic.

Telling your GP

You are not obliged to, and a private prescription does not require GP involvement. But there are situations where it genuinely matters:

• If you have type 2 diabetes or take insulin or a sulfonylurea, whoever manages your diabetes needs to know, because those doses may need adjusting. This is a safety requirement rather than a courtesy.
• If you take blood pressure medicines, weight reduction often lowers blood pressure and you may become over-treated as you lose weight.
• If you are having surgery or any procedure under sedation, your surgical and anaesthetic team need to know well in advance.
• If a new symptom appears that needs investigating independently of your weight-management treatment.

Most people find it simplest to tell their GP practice at the outset, so that anything appearing later is interpreted with the full picture in view.

Which dose will you be prescribed?

For a new Mounjaro initiation, the licensed starting dose is 2.5 mg once weekly1. You do not choose your starting strength, and you should be wary of any provider that lets you.

Dose increases may be considered in 2.5 mg steps after at least four weeks at the current strength, depending on tolerability, response and the prescriber’s assessment. They are not automatic, and the minimum interval is a minimum rather than a schedule. Staying longer at a strength, or staying there permanently, is a legitimate clinical outcome. Our dose schedule guide covers each step in detail.

Why prescriptions are declined

Most requests are approved. Some are not, and it is worth knowing why in advance so that a decline reads as the process working rather than a rejection of you.

You are not charged for treatment that is not approved. Where a decline is about missing information rather than suitability, you will usually be asked for more detail rather than refused outright. And a decline from one provider does not always mean a decline everywhere, because provider-specific criteria go beyond the licence and differ between clinics.

What happens after your prescription is approved

The part most providers say least about, and the part that determines whether your medicine arrives in a usable condition.

Dispatch follows clinical approval and is subject to stock, identity verification and courier cut-off times. We do not promise a guaranteed delivery window, because a provider that does is making a promise about a courier network it does not control.

Dispensing, packaging and delivery

Why cold chain matters

Mounjaro is stored in a refrigerator between 2°C and 8°C before first use and must not be frozen. A pen that has been too warm or has frozen at any point cannot be identified by looking at it, which is why the handling between pharmacy and door matters and why buying from an unregulated seller carries a risk you cannot inspect for.

What to do when it arrives

• Open it promptly and refrigerate the pen as directed in your patient information leaflet
• Do not freeze it, and do not use a pen that has been frozen at any point, even if it has thawed and looks normal
• Inspect the pen — do not use it if the liquid is discoloured or contains particles, or if the pen looks damaged
• Keep it in the original carton to protect it from light
• Never store the pen with a needle attached
• Follow the storage temperatures and in-use period stated in your current UK patient information leaflet rather than any figure quoted elsewhere

Travelling with it

Carry the pen in hand luggage rather than the hold, which is not temperature controlled. Use a cool bag with a temperature pack, without the pen touching the pack directly. Take a travel sharps container and check disposal arrangements at your destination. Our travel and cold chain guide and storage guide go into detail.

What arrives in the box

One KwikPen provides four once-weekly doses and normally covers four weeks of treatment when used as prescribed. You need one pen per month at your current strength, not one per injection.

Your first injection

This is an overview. The Instructions for Use supplied with your pen are the authoritative source and should be read fully before your first injection.

• Once weekly, the same day each week. Any time of day, with or without food.
• Check the pen before use. The liquid should be clear and colourless.
• Use a new needle every time. Reusing needles blunts the tip, increases pain and injection-site reactions, and risks blockage.
• Inject subcutaneously — into the fat layer just under the skin — into the abdomen avoiding the area immediately around the navel, the front of the thigh, or the upper arm.
• Rotate sites with each injection. Repeated use of the same spot can cause lumps or hardening, which affects absorption.
• Hold the pen in place for the full count specified in the Instructions for Use, so the complete dose is delivered.
• Remove the needle immediately afterwards and put it straight into your sharps container.
• Never share your pen, even with a new needle.

Your free monthly clinical review

Included in the price at every stage, not charged separately and not skipped at renewal.

What it covers

• Weight change, and over what period rather than week to week
• Whether side effects are settling, persisting or worsening
• Whether the current strength is right, or whether staying longer is better than escalating
• Any new symptoms, particularly abdominal pain
• Any new medicines, and whether existing ones need reviewing as your weight changes — blood pressure and diabetes medicines in particular
• Eating pattern, protein intake and activity
• Anything you want to raise, including cost

Reordering and repeat supply

You order the strength you have been prescribed, when you need it. There is no automatic billing, no minimum term and no cancellation fee, so if you pause you simply do not place the next order.

Ordering more than one pen

Sometimes possible, subject to clinical assessment and the reason for the request. Supplying several future strengths in advance is usually avoided, because your prescribed dose may change and you could be left with medicine you no longer need. Additional supply may occasionally be considered for circumstances such as extended travel. Approval is not guaranteed.

Switching to Slinic from another provider

Transferring is common and does not usually mean starting the titration again — but it is a clinical decision rather than an administrative one.

What you will need

• Your current strength and how long you have been on it
• The date of your most recent dose
• Evidence of current treatment — a dispensing label, prescription record, letter from your previous provider or order history showing dose and dates
• How you have tolerated treatment and any side effects
• Your current medicines and full medical history
• Weight verification as part of the assessment

You do not need a letter of release from your previous provider, and you do not need an NHS referral.

What the prescriber decides

Whether it is safe to continue at the same strength, reduce it, or restart titration — based on the gap in treatment, the evidence supplied, tolerability and your clinical history. Without evidence of what you have been taking, a prescriber cannot safely continue you at a higher strength, which is why the dispensing label matters. Our guide to switching provider sets out what to bring.

Restarting after a break

People pause treatment for all sorts of reasons — surgery, pregnancy planning, side effects, supply, cost, or simply life. Restarting is straightforward, but it is not always a case of picking up where you left off.

Why a step back is often recommended

Tolerance to the gastrointestinal effects builds during treatment and reduces during a break. Returning directly to a strength you previously tolerated well can produce side effects markedly worse than you remember from the first escalation. A short step back is usually the difference between a comfortable restart and a difficult fortnight, and it is a safety decision rather than an administrative one.

What the prescriber weighs

• How long the gap was
• What strength you were on when you stopped
• Why you stopped, particularly if it was side effects
• Whether anything has changed medically since
• Whether your weight has changed materially

Our guide to restarting after a break covers the clinical reasoning in more detail.

Mounjaro prices at Slinic

A summary. For the full picture — cost per weekly injection, six and twelve-month totals, and a comparison against other UK providers — see our Mounjaro price comparison guide.

Medicine prices are fixed for 2026 and were last verified on 3 August 2026. Delivery charges and availability remain subject to review. The same published price applies to new and returning patients — no code required and no introductory rate that reverts at month two.

Buying Mounjaro without a subscription

Both models are widely used by regulated UK providers and neither is inherently better. They behave very differently, though, and the difference matters most at the point you want to stop.

Slinic operates a pay-per-order model. No automatic billing, no minimum term, no cancellation fee. That is genuinely useful if you may need to pause for surgery, pregnancy planning, side effects or cost — and a meaningful number of people do, at some point in a course of treatment measured in months.

Buying privately versus getting Mounjaro on the NHS

If you qualify for NHS treatment and can access it without a prohibitive wait, that is the right route. Most people currently buying privately do not qualify.

How NHS access works

NICE recommended tirzepatide for weight management in TA1026 in December 20242. NHS England subsequently applied a funding variation allowing a phased implementation across specialist weight management services and primary care rather than immediate universal access3. In the first primary-care cohort, NHS England has stated access is initially for people with a BMI of 40 or more, adjusted for ethnicity, who have been diagnosed with four of the listed weight-related health problems. Cohorts widen sequentially.

NHS prescription charges may apply in England unless you are exempt. Prescriptions are free in Scotland, Wales and Northern Ireland. Our NHS eligibility guide covers both routes.

Safety, side effects and who should not buy Mounjaro

This is a summary. The authoritative source is the current UK Summary of Product Characteristics and the patient information leaflet supplied with your medicine1.

Contraindication

Tirzepatide must not be used by anyone with known hypersensitivity to the active substance or to any of the excipients in the product.

Situations requiring particular caution

• A history of pancreatitis, or symptoms suggestive of it during treatment
• Severe gastrointestinal disease, including gastroparesis, since gastric emptying is slowed
• Diabetic retinopathy, where rapid improvement in glycaemic control has been associated with temporary worsening
• Dehydration risk and kidney function, particularly after a period of vomiting or diarrhoea
• Planned surgery or any procedure involving sedation or anaesthesia — tell your surgical and anaesthetic team well in advance
• Gallbladder disease, since rapid weight loss from any cause increases gallstone risk

Common side effects and how to reduce them

Most are gastrointestinal, most appear during titration or shortly after a dose increase, and most settle as the body adjusts. Nausea, diarrhoea, vomiting, constipation, indigestion, burping, headache, fatigue and injection-site reactions are the ones most people encounter.

• Eat smaller portions — the single most effective adjustment for most people
• Eat slowly and stop when full; fullness arrives earlier than you are used to
• Avoid very fatty and fried food, particularly in the days after a dose increase
• Keep fluids up. Reduced appetite usually reduces drinking too, and mild dehydration worsens nausea, fatigue and constipation
• Do not increase your dose while significant symptoms persist — raise it at your review instead

Pregnancy, breastfeeding and contraception

Tirzepatide is not recommended in pregnancy. If you are planning to conceive, discuss timing with your prescriber in advance, and discuss breastfeeding before starting. Weight reduction can also restore ovulation in people who were not previously ovulating, so contraception is worth planning before your first dose rather than after.

Interactions

Risk of low blood sugar rises substantially when tirzepatide is used alongside insulin or a sulfonylurea, and those doses may need adjusting by the clinician managing your diabetes. Delayed gastric emptying can affect the absorption of some oral medicines. Tirzepatide should not be used at the same time as another GLP-1 receptor agonist or another tirzepatide-containing medicine.

Our full side-effect guide covers management in detail, and our complete Mounjaro guide covers how the medicine works and what to expect from treatment.

Frequently asked questions about buying Mounjaro

Related guides

References

Numbered citations in the text link to the sources below.

1. electronic Medicines Compendium — Mounjaro (tirzepatide) KwikPen, Summary of Product Characteristics and Patient Information Leaflet.
2. NICE TA1026 — Tirzepatide for managing overweight and obesity, December 2024.
3. NHS England — Interim commissioning guidance for NICE TA1026 (tirzepatide), reviewed April 2026.
4. General Pharmaceutical Council — registers of pharmacies and pharmacy professionals.
5. General Pharmaceutical Council — guidance for registered pharmacies providing pharmacy services at a distance, including on the internet.
6. MHRA — guidance and enforcement activity on falsified and unlicensed weight-management medicines.
7. NHS England Digital — Summary Care Records.
8. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
9. MHRA Yellow Card scheme — reporting suspected adverse drug reactions.

Sources accessed 3 August 2026. Where sources conflict, current UK product information and MHRA guidance are treated as the source of truth. Slinic medicine prices are fixed for 2026 and were last verified on 3 August 2026.

Written and clinically reviewed by Shadeia Younis, Superintendent Pharmacist (GPhC No. 2052119) · Last reviewed 3 August 2026. This page is general information and does not replace advice from a qualified healthcare professional. Mounjaro (tirzepatide) is a prescription-only medicine, is supplied only after an individual clinical assessment by a UK-registered prescriber, and is not suitable for everyone. It is licensed for use alongside a reduced-calorie diet and increased physical activity. Individual results vary.